Apple Inc

NASDAQ:AAPL 2:08:05 PM EDT

304.19

-1.74 (-0.57%)

Apple Inc. (NASDAQ:AAPL) Reaches for Enormous Medical Technology Market

Date Published: 7-19-2016

Preface
Apple Inc. (NASDAQ:AAPL) has officially stepped into the enormous medical technology market by partnering with GlaxoSmithKline plc (ADR) (NYSE:GSK).

BREAKING
Apple has partnered with GlaxoSmithKline plc (ADR), its first ever drug company partnership. Apple created ResearchKit, which is a medical platform designed to turn the iPhone into a diagnostic tool for clinical trials and studies.

When Apple Inc. first released ResearchKit it did come with some fan fair. Here's a snippet from an article penned by The Verge:

“
Apple will release five disease-specific apps today. Those apps include an app to track Parkinson's disease symptoms. With it, anyone with an iPhone can contribute to Parkinson's research, Williams said. A second app will help people who suffer from asthma track how often they use their inhaler.

This was already possible with ResearchKit, but the data will now be sent to Mount Sinai Hospital in New York City, Apple's asthma app partner.

”

That same The Verge article reported that Apple had partnered with the University of Oxford, Stanford Medicine and others. The power behind the Apple research it was simply to make clinical trials easier and faster. Given the enormous iPhone user base, the thought has been that ResearchKit would allow drug companies and other researchers to find larger and more diverse populations for a clinical trial in less time.

GlaxoSmithKline plc (ADR) (NYSE:GSK) is the first drug company to take the bait, by creating its own app for the iPhone using the ResearchKit ecosystem. Bloomberg was first to report the study, here's a snippet:

“
GlaxoSmithKline plc (ADR) has started a rheumatoid arthritis study using Apple Inc.'s ResearchKit, marking the first time a drug maker has used the health system for the iPhone to conduct clinical research.

”

Source: Bloomberg

APPLE INC. IT'S BIGGER THAN A LITTLE
This is a much bigger potential market for Apple Inc. than the mainstream media appears to be reporting. If the GlaxoSmithKline plc (ADR) (NYSE:GSK) goes well, Apple's ResearchKit will instantly become a viable, if not preferred, apparatus for clinical trials, which are often so cumbersome and costly, that small biotechnology firms have to partner with larger ones and give up a part of their ownership stake just to get the capital to move forward.

Further, this is the forward momentum needed for the Apple Watch. Back in March, AliveCor, a medical technology company, worked to produce an FDA-cleared EKG technology for mobile devices. TechCrunch reported that "The product is intended to help wearers detect cardiac arrhythmia conditions that can cause stroke, as well as indicate whether your heart rate and rhythm are normal."

The image above from ifans, shows the stunning reality that the Apple Watch allowed: "Press on the band with your thumb to take a reading."

MOVING FORWARD
The first version of the Apple Watch has actually sold significantly better than the first version of the iPhone, though the press would have you believing otherwise. But more broadly, Apple Inc. (NASDAQ:AAPL) is looking to broaden its business outside of just the iPhone. While the Apple Car, Apple Pay and Apple TV as a cable bundler all have promise, the move into medical technology for Apple could not only be huge for the company in terms of the earnings potential, but it could also actually help the world.

WHY THIS MATTERS
The seismic disruption that will come with improved medical technology and artificial intelligence will be fantastical. It's identifying trends like this that allows us to find the 'next Apple' or the 'next Google.' This is what CML Pro does. Our research sits side-by-side with Goldman Sachs, Morgan Stanley and the rest on professional terminals, but we are the anti-institution and break the information advantage the top .1% have.

Each company in our 'Top Picks' is the single winner in an exploding thematic shift like artificial intelligence, Internet of Things, drones, biotech and more. In fact, here are just two of the trends that will radically affect the future that we are ahead of:

That chart plots the growth in 4G usages worldwide and how it will grow from 330 million people today to nearly 2 billion in five years. This is the lifeblood fueling every IoT and mobile device on the planet and CML Pro has named the single winner that will power this transformation. Then there's cyber security:

Market correction or not, recession or not, the growth in this area is a near certainty, even if projections come down, this is happening. CML Pro has named the single best cyber security stock to benefit from this theme.

These are just two of the themes we have identified and this is just one of the fantastic reports CML Pro members get along with all the visual tools, the precious few thematic top picks for 2016, research dossiers and alerts. For a limited time we are offering CML Pro at a 90% discount for $10/mo. with a lifetime guaranteed rate. Join Us: Get the most advanced premium research delivered to your inbox along with access to visual tools and data that until now has only been made available to the top 1%.

Thanks for reading, friends. The author is long Apple shares in his personal account.